Stock MEDINCELL
Add to a list
To use this feature you must be a member
Log inSign up

MedinCell Share Price LIQUIDNET SYSTEMS

Equities

FR0004065605

Pharmaceuticals

End-of-day quote LIQUIDNET SYSTEMS
Other stock markets
 		5-day change 1st Jan Change
- EUR -.--% Intraday chart for MedinCell -.--% -.--%
10/06 Transcript : MedinCell S.A., 2024 Earnings Call, Jun 10, 2024
10/06 Medincell: a 'new era' after a 'pivotal' 2023 CF

Financials

Sales 2024 90.32L 96.66L 81Cr Sales 2025 * 3.6Cr 3.85Cr 322Cr Capitalization 41Cr 43Cr 3.62TCr
Net income 2024 -2.5Cr -2.68Cr -223.61Cr Net income 2025 * - 0 0 EV / Sales 2024 30.5 x
Net Debt 2024 * 4.7Cr 5.03Cr 420.09Cr Net Debt 2025 * 3.2Cr 3.42Cr 286.22Cr EV / Sales 2025 * 12.1 x
P/E ratio 2024 *
-15.3 x
P/E ratio 2025 *
-51 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 50.05%
More Fundamentals * Assessed data

Chart MedinCell

Dynamic Chart

Latest news about MedinCell

Transcript : MedinCell S.A., 2024 Earnings Call, Jun 10, 2024
Medincell: a 'new era' after a 'pivotal' 2023 CF
MedinCell S.A. Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Medincell: share price falls after disappointing clinical study CF
Transcript : MedinCell S.A. - Special Call
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial CI
Medincell: share price rises on resumption of trading CF
CAC40: remains in green in a neglected market CF
Medincell: positive results in schizophrenia CF
Medincell Listing Temporarily Suspended on Euronext Paris MT
Teva and Medincell's schizophrenia drug meets main goal of late-stage study RE
Teva Pharmaceuticals and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-?749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia CI
CAC40: in green, builds on previous day's momentum CF
Medincell: listing suspended pending a press release CF
Medincell: share price rises following agreement with AbbVie CF
More news

Latest transcript on MedinCell

Logo MedinCell
MedinCell S.A., 2024 Earnings Call, Jun 10, 2024
More transcripts

Analyst Recommendations on MedinCell

MedinCell: share price continues to rise, Jefferies to buy CF
MedinCell: share price surges, broker in support CF
MEDINCELL : Oddo raises its target price on the stock CF
More recommendations

Press releases MedinCell

MedinCell S A : Inside Information / Other news releases PU
Medincell Joins the Euronext Tech Leaders BU
Medincell Publishes Its Consolidated Annual Financial Results BU
Medincell: Publication of the Financial Results for the 2023-2024 Fiscal Year and Videoconference on Monday, June 10, 2024 BU
Medincell’s Partner Teva presented New Data Providing Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) from Invega Sustenna® (paliperidone palmitate) BU
More press releases

News in other languages on MedinCell

MedinCell S A : Informations privilégiées / Autres communiqués
Euronext voit une fenêtre pour les cotations de sociétés tech
Medincell rejoint l’indice Euronext Tech Leaders
Medincell : une 'nouvelle ère' après une année 2023 'pivot'
MedinCell S A : a réduit sa perte en 2023
More news

Managers and Directors - MedinCell

Managers TitleAgeSince
Christophe Douat CEO
 Chief Executive Officer 60 09/03/09
Stéphane Postic DFI
 Director of Finance/CFO 50 01/23/01
Adolfo Lopez-Noriega CTO
 Chief Tech/Sci/R&D Officer - 01/15/01
Members of the board TitleAgeSince
Sabri Markabi BRD
 Director/Board Member - 05/17/05
Tone Kvåle BRD
 Director/Board Member 55 13/22/13
Virginie Lleu BRD
 Director/Board Member - 25/16/25
More insiders

Company Profile

MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. As of March 31, 2023, the company had a portfolio of 2 products in phase 3 clinical development and 6 products in preclinical development. Its most advanced product, mdc-IRM/UZEDYTM for the treatment of schizophrenia, has received marketing authorization in the United States.
Sector
Pharmaceuticals
Calendar
12/09/2024 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Ratings for MedinCell

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
13.94 EUR
Average target price
19.24 EUR
Spread / Average Target
+38.02%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+50.70% 79TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.96% 63TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.15% 35TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.77% 33TCr
ABBVIE INC. Stock AbbVie Inc.
+8.79% 30TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.02% 25TCr
ROCHE HOLDING AG Stock Roche Holding AG
+1.27% 22TCr
NOVARTIS AG Stock Novartis AG
+11.95% 22TCr
AMGEN INC. Stock Amgen Inc.
+3.68% 16TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MEDCL Stock
  4. Stock